Skip to main content

Grifols

Grifols, S.A. is a Spanish multinational pharmaceutical enterprise that specializes in the collection of human blood plasma and the production of plasma-derived protein therapeutics. The company operates through core business segments covering Bioscience, Diagnostic, and Hospital divisions. Its principal product offerings encompass human immunoglobulins, albumin, alpha-1 antitrypsin, clotting factors, and specialized clinical diagnostic reagents. Revenue is driven primarily through the commercial sale of plasma protein therapies and laboratory diagnostics to hospitals and healthcare providers globally. The primary end markets comprise patients suffering from immunodeficiencies, bleeding disorders, and rare chronic diseases. As one of the world's largest producers of plasma-derived medicines, the enterprise maintains an extensive global network of plasma donation centers. Headquartered in Barcelona, Spain, Grifols SA is publicly listed on the Bolsa de Madrid and NASDAQ.

29 of the funds FundTelligence covers report a position in Grifols.

Legal name
Grifols SA
Sector
Health Care
Country
Spain
Funds holding it
29

Funds holding Grifols

Showing the 8 largest of 29 funds holding it.

Loading...